![Baby's hand holding its mother's finger](https://seraprognostics.com/wp-content/uploads/sites/2/2022/02/iStock-905836972-About-Us2-1600x600.jpg)
Newsroom
Latest News
News
Sera Prognostics Completes Enrollment of Large, Multicenter, Prospective Clinical Study of PreTRM® Test
Nov. 27, 2018 — Sera Prognostics, The Pregnancy Company(™), announces that it has completed enrollment of 5,009 women into its prospective real-time study, “A Multicenter Assessment of a Spontaneous Preterm Birth Risk Predictor (TREETOP).”
News
Intermountain Health and Christiana Care Health System Begin Enrollment on Two Landmark Preterm Birth Studies with PreTRM® Test
July 1, 2018 – Sera Prognostics®, The Pregnancy Company™, announces the recent launch of two new preterm birth studies using the PreTRM® test to identify high-risk mothers for intervention care.
News
Sera Prognostics Appoints Dr. Garrett K. Lam as Chief Medical Officer
Sera Prognostics, Inc., a women’s healthcare company,
announced today that Garrett K. Lam, M.D., FACOG, will be joining the company as chief
medical officer on September 4, 2018. Dr. Lam will direct all clinical development activities for
Sera as the company achieves its vision to be The Pregnancy Company™. He will lead a
group of talented clinical operations professionals who support Sera’s collaborations with
research teams across the globe.
News
Sera Prognostics Collaborates with Christiana Care Health System to Launch New Preterm Birth Study with PreTRM® Test
June 19, 2018 — Sera Prognostics announced today that the first patient has been enrolled in the AVERT PRETERM TRIAL. This is the second intervention study to use Sera’s PreTRM® test to identify women at high risk of early delivery that will receive proactive interventions with the goal of reducing the rate of premature delivery and improving newborn health. The principal investigator for the study is Matthew Hoffman, M.D., MPH, FACOG, Marie E. Pinizzotto, M.D., Endowed Chair of Obstetrics and Gynecology at Christiana Care Health System in Wilmington, Delaware.
News
Intermountain Healthcare Launches New Study to Determine Benefit of Proactive Interventions in Reducing Premature Births
May 29, 2018 – Intermountain Healthcare announced it is launching the first study of its kind that will use Sera’s PreTRM® to identify those at risk for premature birth, and, in those with high risk, to evaluate the impact of early interventions designed to prolong their pregnancy and reduce the rate of premature delivery.
News
Key Strategies for Implementing Proteomics-Based Tests Across Disease States Highlighted in Current Opinion in Biotechnology
Seattle, WA and Salt Lake City, February 12 – Sera Prognostics, in collaboration with The Institute for Systems Biology and Integrated Diagnostics (Indi), today announced a paper entitled, “The building blocks of successful translation of proteomics to the clinic,” by Leroy Hood and colleagues published online in Current Opinion in Biotechnology.
News
Sera Prognostics to Present at the 11th Annual Canaccord Genuity Medical Technologies and Diagnostics Forum
SALT LAKE CITY, November 6, 2017–Sera Prognostics today announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, will present at the upcoming Canaccord Genuity Medical Technologies and Diagnostics Forum in New York City. Dr. Critchfield’s presentation will take place at 2:30 PM E.T. on Thursday, November 9th, at the Westin Grand Central Hotel.
News
Sera Prognostics to Present at the Baird 2017 Global Healthcare Conference
SALT LAKE CITY, September 5, 2017 –Sera Prognostics today announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, will present at the upcoming Baird Global Healthcare Conference in New York City. Dr. Critchfield’s presentation will take place at 9:05 AM E.T. on Thursday, September 7th, at the InterContinental New York Barclay Hotel.
News
Sera Prognostics Receives Accreditation from College of American Pathologists
SALT LAKE CITY, June 29, 2017– Sera Prognostics, Inc., a women’s healthcare company, announced today that the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to Sera Prognostics, Inc., based on results of a recent on-site inspection as part of the CAP’s Accreditation Programs.
News
Sera Prognostics Announces Analytical Validation Study
SALT LAKE CITY, June 26, 2017– Sera Prognostics, Inc., a women’s healthcare company, announced today that its recent analytical study, “Analytical Validation of Protein Biomarkers for Risk of Spontaneous Preterm Birth” has been published in the June issue of Clinical Mass Spectrometry. The study details a rigorous analytical validation of Sera’s liquid chromatography/mass spectrometry (LC/MS) platform for sensitive later-generation Agilent mass spectrometers. This work confirms Sera’s ability, across instrument generations, to perform accurate analytical measurements required to provide individualized determination of a woman’s risk of spontaneous early delivery through Sera’s groundbreaking PreTRM® test. The PreTRM® test is the first and only broadly clinically-validated blood test that provides an early and individualized prediction of preterm birth risk.